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Although the hepatocyte growth factor-like protein (HLP) shares a 50% homology with the hepatocyte growth factor, the biological function of 
HLP has remained unknown. Addition of conditioned medium of COS-7 cells transfected with the expression plasmid for HLP cDNA to cultures 
of resident peritoneal macrophages induced specific activation of macrophages, and the factor which stimulates macrophages was purified from 
the conditioned medium. The purified protein showed M, of 85 kDa on SDS-PAGE, and this M, is in agreement with that of macrophage- 
stimulating protein (MSP) previously purified from human serum, as well as with the predicted M, of HLP. Amino acid composition of the purified 
protein coincided with the compositions of human HLP and MSP. Together with the finding that the partial amino acid sequences of MSP are 
highly homologous to that of HLP, we conclude that the biological function of HLP is to activate macrophages and that HLP and MSP are identical 
molecules. 
Hepatocyte growth factor; Hepatocyte growth factor-like protein; Macrophage stimulating protein; HGF-family 
1. INTRODUCTION 
Hepatocyte growth factor (HGF) was first discovered 
and isolated as a potent mitogen for adult rat hepato- 
cytes in primary culture [l]. Purification [24] and mo- 
lecular cloning [5-91 of HGF revealed that HGF is a 
disulfide-linked heterodimer molecule composed of a 69 
kDa a-subunit containing four kringle domains and a 
34 kDa B-subunit containing a serine protease-like do- 
main, thereby possessing 38% homology in amino acid 
sequence with plasminogen. HGF is now known to be 
a mesenchymal-derived pleiotropic factor (reviewed in 
[lO,ll]) which acts as a mitogen [9,12], motogen (en- 
hancement of cell motility) [13] and morphogen [14] 
predominantly for various epithelial cells, and it also 
functions as a tumor suppresser [15-l 71. HGF is also 
known to function as ‘trophic factor’ for regeneration 
of various organs (reviewed in [lS]), including the liver 
[19,20], kidney [21-231, and lung [24]. On the other 
hand, a high affinity cellular receptor for HGF was 
identified to the c-met proto-oncogene product with an 
intracellular tyrosine kinase domain [25-271. 
protein was named hepatocyte growth factor-like pro- 
tein (HLP) [28]. HLP has four kringle domains and a 
serine protease-like domain and their amino acid se- 
quences have a 50% homology with HGF [28]. While 
researching the biological activity of HLP, we observed 
that partial amino acid sequences of macrophage stimu- 
lating protein (MSP), previously purified from human 
serum [29], were highly homologous with those of HLP 
PI. 
Based on the amino acid sequence homology, we 
asked whether HLP and MSP may be identical mole- 
cules. We now report convincing evidence that HLP and 
MSP are indeed identical. The biological function of 
HLP is to induce activation of macrophages. 
2. MATERIALS AND METHODS 
2.1. cDNA cloning of human HLP and construction of the expression 
plasmid 
While many growth factors were classified into cer- 
tain families, according to structural similarity, growth 
factors belonging to the HGF family have only recently 
been identified. cDNA encoding a unique protein with 
a domain structure similar to that of HGF was isolated 
from a human liver cDNA library, and the putative 
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Human HLP cDNA was cloned by polymerase chain reaction 
(PCR). Single-strand cDNAs were synthesized from 1 pg of human 
liver poly(A) RNAs, using random primers in the presence of M-MLV 
reverse transcriptase (BRL, Gaithersburg, MD). The upstream half 
1 .l kb and downstream half 1.2 kb of human HLP cDNA were 
amplified from single-strand cDNAs by PCR using primers as follows: 
Sense primer-l (human cDNA nucleotide sequence -57 to -39), 5’- 
TCGAAGCTTCACAACTTCCCGGATGG-3’; antisense primer-l 
(1077-1094), 5’-ACGTCGTCTGTACAACGC-3’; sense primer-2 
(932-949), 5’-TCCCTCATCAGCACCGAT-3’; antisense primer-2 
(21462163), 5’-CTGTCTAGACCAAGGCATATGGCATCA-3’ [28]. 
PCR products were sequenced, then the upstream half and the down- 
stream half were ligated to construct a full-size open reading frame of 
HLP cDNA at the BbeI site present in both fragments [28]. 
Mammalian expression plasmid, pUC-SRa was constructed by in- 
serting an SaZI fragment of pcDL-SRtx [30] which contains the SRa 
promoter and poly(A) signal into the pUCl9 plasmid. Human HLP 
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cDNA expression plasmid, pUC-SRuIHLP was constructed by insert- 
ing a 2.2 kb full-size open reading frame of human HLP cDNA 
downstream of SRa promoter. 
2.2. Cell culture and transfection of plasmid 
COS-7 cells were cultured in Dulbecco’s modified Eagle’s (DME) 
medium supplemented with 10% fetal calf serum (FCS). Ten pg of 
plasmid was mixed with 400@ml of DEAE-Dextran and transfected 
into COS-7 cells in DME medium containing 100 PM chloroquine. 
Following a culture period of 48 h, the medium was changed to 
serum-free DME medium, the cells were further cultured for 72 h, and 
the medium was used for purification of HLP. 
2.3. Northern blot analysis 
Total RNA was prepared from COS-7 cells by the acid guanidium 
phenol chloroform method [31] at 24 h after the transfection of plas- 
mid. Five pg of RNAs were denatured and electrophoresed in 1% 
agarose/formaldehyde g l. RNAs were transferred to a nylon mem- 
brane (Amersham) and hybridized with the 32P-labeled 2.2 kb human 
HLP cDNA fragment. 
2.4. Detection of MSP activity 
MSP activity was measured based on the ability to induce attach- 
ment and spreading of macrophages i olated from C3H mouse [32]. 
Resident peritoneal macrophages uspended in RPMI-1640 medium 
supplemented with 10% FCS at 5 x lo5 cells/ml were added to each 
well of a 96-well plate, and test samples were added to the culture. 
After culturing the cells for 6 h, the adhesion and spreading of macro- 
phages were observed. One unit of MSP activity was defined as the 
reciprocal of the maximal dilution fold of samples within a concen- 
tration range in which MSP activity was obvious after the dilution. 
2.5. Purification of HLPIMSP from conditioned medium 
Serum-free conditioned medium (360 ml) obtained from COS-7 cells 
transfected with pUC-SRu/HLP was dialyzed against 10 mM phos- 
phate buffer (pH 6.7) containing 0.2 M NaCl, and loaded onto 48 ml 
of heparin Sepharose (Pharmacia, Uppsala) column equilibrated with 
the same buffer at 4°C. The column was washed with 200 ml of the 
same buffer containing 0.01% Tween 80, and bound proteins were 
eluted with a 240 ml linear gradient of 0.2-1.2 M NaCl in the same 
buffer. MSP active fractions obtained from affinity chromatography 
were diluted with 4 volumes of 10 mM phosphate buffer @H 6.7) and 
loaded onto a 4 ml CM Sepharose (Pharmacia) column equilibrated 
with the same buffer containing 0.1 M NaCl. The column was washed 
with 50 ml of the buffer, after which the bound proteins were eluted 
with a 80 ml linear gradient of 0.1-0.3 M NaCl in 10 mM phosphate 
buffer (pH 6.7). After active fractions from CM Sepharose chromatog- 
raphy (13 ml) were concentrated using Centriprep (Amicon, Inc., 
Beverly, MA) to 0.5 ml, 0.25 ml of concentrated sample was loaded 
onto a Superose-12 column (Pharmacia) equilibrated with 10 mM 
phosphate buffer (pH 6.7) containing 0.1 M NaCl and fractionated at 
0.5 ml/tube. 
2.6. SDS-PAGE and amino acid analysis 
SDS-PAGE was performed by the method of Laemmli [33] using 
a lo-20% gradient gel. Proteins were visualized by silver staining, 
using a Wako silver staining kit (Wake Pure Chemical, Osaka). MSP 
active fractions pooled from FPLC using a Superose-12 column were 
further purified by reverse-phase high-performance liquid chromatog- 
raphy (HPLC), using a Phenyl-5PW column (Tosoh, Tokyo). Ten pug 
of purified protein was hydrolyzed with HCI and analyzed using an 
automated amino acid analyzer (HITACHI L-8500). 
3. RESULTS 
3.1. MSP activity in conditioned medium of COS-7 cells 
The expression plasmid of HLP (pUC-SRaIHLP) or 
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Fig. 1. Expression of human HLP mRNA in COS-7 cells transfected 
with the expression plasmid encoding human HLP cDNA. The expres- 
sion plasmid of HLP (pUC-SRaIHLP) or mock plasmid (pUC-SRa) 
was transfected into COS-7 cells and the expression of human HLP 
mRNA was analyzed by Northern hybridization. Total RNA was 
prepared from the cells at 24 h after transfection. Ribosomal RNAs 
stained with ethydium bromide are shown in the lower photograph, 
to indicate the amount of RNAs loaded on to the gel. 
mock plasmid (pUC-SRol) was transfected into COS-7 
cells and the expression of human HLP mRNA was 
analyzed by Northern hybridization (Fig. 1). A tran- 
script of about 2.5 kb of HLP mRNA was specifically 
expressed in COS-7 cells transfected with pUC-SRaI 
HLP, but it was not detected in COS-7 cells transfected 
with mock plasmid, pUC-SRa. Thus, HLP mRNA was 
specifically expressed in COS-7 cells transfected with the 
expression plasmid containing HLP cDNA. 
To examine whether COS-7 cells expressing HLP 
mRNA produce a factor possessing MSP activity, the 
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Fig. 2. Activation of mouse peritoneal macrophages by the addition 
of conditioned medium of COS-7 cells. The conditioned medium of 
COS-7 cells transfected with pUC-SR& (A) or pUC-SRaIHLP (B) 
were added to culture of macrophages and cells were further cultured 
for 6 h. Bars represent 50 pm. 
conditioned medium of COS-7 cells was assayed for 
MSP activity. When conditioned medium from COS-7 
cells expressing HLP mRNA was added to cultures of 
murine peritoneal macrophages, the cells rapidly ad- 
hered and spread out, within 6 h (Fig. 2). In contrast, 
the addition of conditioned medium from COS-7 cells 
transfected with mock plasmid induced no morphologi- 
cal changes in the macrophages. Thus, the culture me- 
dium-secreted HLP from COS-7 cells contains high lev- 
els of MSP activity. 
3.2. Purification of a factor with MSP activity from the 
conditioned medium 
To characterize and purify the factor with MSP activ- 
ity present in the conditioned medium, the conditioned 
medium of COS-7 cells transfected with pUC-SRaIHLP 
was first applied to a heparin Sepharose column. More 
than 90% of the proteins applied to the column were not 
adsorbed and MSP activity was not detected in the flow- 
through fraction. When proteins were eluted with an 
Table I 
Summary of purification of the factor with MSP activity 
Purification step Protein Activity Specific Recovery Purity 
@g) (U x lo-‘) activity (%) (fold) 
(%g) 
Conditioned 1.49 x 10’ 36 0.24 100 1 
medium 
Heparin- 2.05 x 10’ 18 8.78 50 36.6 
Sepharose 
CM-Sepharose 45.2 5.6 124 15.6 517 
Superose 12 16.2 3.2 198 8.9 825 
Protein concentration was determined from the absorbance at 280 nm 
of each fraction. One unit of MSP activity was defined as the recipro- 
cal of the maximal dilution fold of samples within a concentration 
range in which MSP activity was evident after the dilution. 
increasing concentration of NaCl, MSP activity was 
detected in fractions eluted with 0.40.6 M NaCl (Fig. 
3A). MSP-active fractions from the heparin Sepharose 
column werre subsequently applied to a CM Sepharose 
column. When adsorbed proteins were eluted with the 
NaCl concentration gradient, MSP activity was eluted 
with about 0.15 M NaCl, overlapping with a major peak 
at A,,, (Fig. 3B). MSP-active fractions from cation- 
exchange chromatography were further purified by mo- 
lecular sieve chromatography, using a Superose-12 col- 
umn. After this chromatography, MSP activity over- 
lapped with a single peak of Azlo (Fig. 3C). 
Table I summarizes the purification of a factor pos- 
sessing MSP activity. Starting from 360 ml of condi- 
tioned medium, the factor was purified 800-fold with a 
9% recovery and 16pg of purified protein was obtained. 
3.3. SDS-PAGE and amino acid analysis 
Profiles of proteins at each step of purification were 
analyzed by SDS-PAGE under non-reducing condition 
(Fig. 4). Purified protein with MSP activity showed a 
single band with an apparent M, of 85 kDa. When 
SDS-PAGE was performed under reducing conditions, 
HLP shows a single band of 85 kDa (not shown), 
thereby indicating that HLP was purified as a single- 
chain proform. This value estimated with SDS-PAGE 
is in good accord with 80,325 Da, the M, calculated 
from the nucleotide sequence of human HLP cDNA 
[28], and close to 70 kDa, the M, of purified MSP from 
human serum [29]. Since there are three potential N- 
linked glycosylation sites in the amino acid sequence of 
human HLP [28], differences among these M, may be, 
at least, due to differences in the degree of glycosylation. 
For further confirmation, the amino acid composi- 
tion of the purified protein was analyzed and compared 
with the composition of human HLP deduced from the 
nucleotide sequence [28], as well as that of MSP purified 
from human serum [29] (Table II). The amino acid com- 
position of the purified protein totally coincided with 
the composition of HLP deduced from the nucleotide 
sequence indicating that the purified protein with MSP 
activity is human HLP. Although significant differences 
are obvious in a few amino acids between the purified 
protein (HLP) and MSP, these differences may be 
caused by impurity in MSP preparation. Except for a 
few amino acids, amino acid compositions of both pro- 
teins are very much the same, suggesting that HLP and 
MSP are identical molecules. 
4. DISCUSSION 
The present paper provides evidence that HLP has 
potent biological acitivity to activate macrophages and 
that HLP is identical to MSP, as based on: (i) the me- 
dium from COS-7 cells expressing human HLP mRNA 
specifically contained a factor which activates macroph- 
ages; (ii) the M, of a protein purified from the condi- 
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Fig. 3. Elution profiles of MSP activity from conditioned medium of 
COS-7 cells transfected with pUC-SRaIHLP on column chromatogra- 
phies. (A) Aftinity chromatography with heparin Sepharose; (B) Cat- 
ion-exchange chromatography with CM Sepharose; (C) Molecular 
sieve chromatography with Superose-12. Fractions indicated by bars 
were pooled for the next purification step. 
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Fig. 4. Protein protiles of MSP-active fractions of each purification 
step after SDS-PAGE. Lane 1, conditioned medium of COS-7 cells; 
lane 2, active pool after heparin Sepharose; lane 3, active pool after 
CM Sepharose; lane 4, active pool after Superose-12. After electro- 
phoresis, proteins were fixed, and visualized by silver staining. Stand- 
ard proteins used for the determination of M, were phosphorylase B
(97 kDa), bovine serum albumin (66 kDa), ovalbumin (45 kDa), car- 
bonic anhydrase (31 kDa), and soybean trypsin inhibitor (22 kDa). 
tioned medium, based on the biological activity to stim- 
ulate macrophages, corresponded to 85 kDa, a value 
with close similarity with the predicted M, for human 
HLP, as well as with the iW, of MSP; (iii) the amino acid 
composition of the 85 kDa protein significantly corre- 
sponded with compositions of human HLP and MSP. 
Although HLP has the same domain structure as 
HGF, several proteins that contain kringle domains and 
a serine protease-like domain have been characterized 
as proteolytic enzymes involved in blood coagulation 
and fibrinolysis, including factor XII, prothrombin, tis- 
sue plasminogen activator, urokinase plasminogen acti- 
vator, and plasminogen [34]. Although both HGF and 
HLP also have a serine protease-like domain, three 
triad amino acids (His, Asp, Ser) found in the active site 
of a serine protease domain are substituted by other 
amino acids, in both HGF and HLP [5,28]. Consistent 
with these substitutions, HGF has no proteolytic activ- 
ity [5], and thus it is unlikely that HLP has proteolytic 
activity. Therefore, HGF and HLP are considered to 
belong to a distinct cytokine family, because these mol- 
ecules are functionally distinguishable from proteolytic 
enzymes, although both have a significant structural 
similarity to proteases. 
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Processing of single-chain HGF to two-chain heter- 
odimeric HGF is known to be coupled with the activa- 
tion of pro-HGF and serum-derived serine protease is 
responsible for the activation [35]. Similarly, purified 
single-chain HLP did not show MSP activity when as- 
sayed under serum-free conditions (not shown). Since 
MSP activity was usually assayed under serum-contain- 
ing conditions, single-chain pro-HLP might be acti- 
vated during the assay for MSP. Indeed, when single- 
chain HLP was pretreated with serum, MSP activity 
was induced in a dose- and time-dependent manner, 
even when assayed under serum-free conditions (not 
shown). Single chain pro-HLP may be activated 
through processing by serum-derived protease( 
Many growth factors are classified into distinct fami- 
lies based on structural similarity, and growth factors 
that belong to the same family exert biological activities 
through either the same receptor or through structurally 
highly related receptors. Because the HGF receptor is 
a c-met proto-oncogene product [25-271, HLP may 
exert activity through a receptor structurally related to 
the c-met/HGF receptor. In this context, a novel recep- 
tor-type tyrosine kinase ‘RON’ which belongs to the 
c-met/HGF receptor family has been cloned but the 
natural ligand is unknown [36]. It is worth noting that 
the gene for RON is located at locus p21 on human 
chromosome 3 [36], and this locus corresponds to that 
of the human gene for HLP [28]. Taken together with 
the finding that the genes for HGF (7q21) and c-met 
(7q21-3 1) are both located on the long arm of human 
chromosome 7 [3740], the ligand for RON may possi- 
bly be HLP 
HGF is a mesenchymal-derived factor with plei- 
Table II 
Amino acid composition of 85 kDa protein 
Mol % 
Amino acid Purified protein HLP’ MSP2 
Asp 9.46 9.88 6.98 
Thr 6.12 6.64 6.36 
Ser 4.35 4.94 5.12 
GlU 12.8 12.4 10.1 
Pro 8.14 8.64 9.92 
Gly 12.5 9.88 18.1 
Ala 6.11 5.40 9.15 
Val 7.21 6.19 8.06 
Met 0.91 1.54 1.24 
lle 1.76 2.31 2.02 
Leu 7.63 8.18 1.29 
Tyr 2.45 2.93 1.71 
Phe 3.45 3.86 2.79 
His 3.61 3.86 2.64 
LYS 3.73 3.40 3.41 
Arg 9.16 9.26 5.12 
‘Deduced from the nucleotide sequence without cysteine and trypro- 
phane. 
“Reported by Skeel et al. [29]. 
otropic action. It induces mitogenesis [9,12] and moto- 
genesis [13,41,42], and has unique morphoregulatory 
functions, including the induction of tubule formation 
in vitro [14,43&l]. This factor has also been well charac- 
terized as a ‘trophic factor’ for regeneration of various 
organs such as liver [18,19], kidney [21-231, and lung 
[24]. Thus, HGF is a uniquely suited molecule to con- 
struct the normal tissue architecture during develop- 
ment and tissue regeneration. While biological and 
physiological functions of HLP are the subject of exten- 
sive research, we speculate that HLP may be involved 
in self-defense responses during inflammatory reactions 
caused by infections and tissue injury, by activating 
macrophages. Finally, we propose that known and yet 
to be identified members of the HGF family may play 
important roles in unique self-defense systems responsi- 
ble for the regeneration of tissues and organs, and for 
the maintenance of tissue homeostasis. 
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